# Aquestive Therapeutics, Inc. (AQST) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Aquestive Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/AQST/mda/fy2025/): filed 2026-03-04; accession 0001398733-26-000018 (https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/AQST/mda/fy2024/): filed 2025-03-05; accession 0001628280-25-010506 (https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm)
- [FY 2023 MD&A](/company/AQST/mda/fy2023/): filed 2024-03-05; accession 0001628280-24-009010 (https://www.sec.gov/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm)
- [FY 2022 MD&A](/company/AQST/mda/fy2022/): filed 2023-03-31; accession 0001628280-23-010180 (https://www.sec.gov/Archives/edgar/data/1398733/000162828023010180/aqst-20221231.htm)
- [FY 2021 MD&A](/company/AQST/mda/fy2021/): filed 2022-03-08; accession 0001628280-22-005393 (https://www.sec.gov/Archives/edgar/data/1398733/000162828022005393/aqst-20211231.htm)

Back to /company/AQST/